PVI
CTKB icon

Pura Vida Investments’s Cytek Biosciences CTKB Stock Holding History

Pura Vida Investments’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-420,749
Closed -$4.3M – 101
2022
Q4 		$4.3M Sell
420,749
-106,415
-20% -$1.43M 0.22% 98
2022
Q3 		$7.76M Buy
527,164
+50,000
+10% +$649K 0.45% 59
2022
Q2 		$5.12M Buy
477,164
+52,587
+12% +$523K 0.3% 88
2022
Q1 		$4.58M Buy
424,577
+2,800
+0.7% +$37.8K 0.15% 128
2021
Q4 		$6.88M Sell
421,777
-22,591
-5% -$473K 0.25% 97
2021
Q3 		$9.51M Buy
+444,368
New +$10.5M 0.29% 89

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Pura Vida Investments's CTKB Position: Q1 2023 in Review

Pura Vida Investments sold out of Cytek Biosciences (CTKB) in Q1 2023, closing a stake of 420,749 shares — an estimated $4.3M sold.

Pura Vida Investments first reported a position in CTKB in Q3 2021 and held it in 6 quarters. The position peaked at $9.51M in Q3 2021. 102 funds tracked by Wall St. Rank hold CTKB as of Q1 2023.

  • Pura Vida Investments reported no remaining Cytek Biosciences position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 420,749 Cytek Biosciences shares in Q1 2023, an estimated $4.3M.
  • Pura Vida Investments first reported a position in Cytek Biosciences in Q3 2021 and held it in 6 quarters.
  • Pura Vida Investments's Cytek Biosciences position peaked at $9.51M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.